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Abstract
Background: Pilocytic astrocytomas (PAs) are slow growing neoplasms and usually located at the cerebellum.
There has been certainty regarding the truthful benefit of surgical resection for patients with PA. Gross total
resection (GTR) of PAs, especially those being situated in deep regions, remains a surgical challenge. Generally,
they are considered as benign and usually develop in young patients. PAs, belonging to WHO I can be cured by
radical resection. The patients with PA have excellent prognosis if complete resection can be conducted. The use
of fluorescein in vermis PA surgery has not been yet reported. Our data presents fluorescein facilitates surgical
resection of vermis PA.
Methods: Five milligrams per kilogram of fluorescein sodium was intravenously injected directly before general
anesthesia for the three patients with PA. The yellow 560 filter was employed for microsurgical tumor resection.
Surgical outcomes were assessed concerning the extent of resection.
Results: Most portion of PA in the three cases was found to be highly fluorescent after intravenous fluorescein
sodium injection, which markedly enhanced tumor visibility. Gross total resection in all of the patients was achieved
without further neurological deficits. No adverse effects and complications resulting from fluorescein sodium were
observed over the postoperative course.
Conclusions: Intraoperative guidance by fluorescein sodium as a new, simple, safe, and practical procedure can
enhance the fidelity of tumor tissue and increase the possibility of completely resecting PAs.
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Background
Pilocytic astrocytomas (PA) is a unique subtype of gli-
oma in clinical behavior [1]. A large number of clinical
studies have repeatedly underlined the value of surgical
treatment for patients with PAs [2]. The extent of resec-
tion had a powerful influence on the progression-free
survival (PFS). The fact that has been constantly shown
to be crucial for overall survival (OS) and PFS is that
patients benefit complete resection of PAs.3 Complete
resection is a goal of tumor removal during open
surgery. Fluorescein sodium can make tumor tissue ap-
pear yellowish, which can be visualized against a normal
background. This can help to identify the target and thus
facilitate total tumor removal under microscopy. To the
best of my knowledge, the use of fluorescein sodium in
vermis PAs’ surgery has not been yet reported.
Methods
Informed consents were obtained from patients with ver-
mis PAs about the use of fluorescein sodium. Three pa-
tients had been surgically treated at our neurosurgical
department. Comprehensive data including preoperative
and postoperative MRI scans within 72 h was docu-
mented. Surgery was performed with a surgical micro-
scope equipped with a yellow 560 filter. A predefined dose
of 5 mg/kg of fluorescein sodium was intravenously
injected via a central line immediately before general
anesthesia. All patients were admitted to the neurosurgical
common care unit for postoperative care. Postoperative
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MRI images were reviewed for any contrast-enhancing re-
sidual tumor tissues by a neuroradiologist and neurosur-
geon. The presence of PAs was confirmed in all patients
by a neuropathologist. The surgical reports were screened
with reference to the degree of fluorescent sodium stain-
ing: “bright/helpful” versus “effectively no fluorescence/
not helpful”. The study was approved by the local ethics
committee.
Radiological examination
Vermis PAs, accounting for a low rate in the poster-
ior fossa PAs, are commonly hypodense on precon-
trast CT scans and hyperdense on precontrast MRIs.
Vermis PAs usually do not have radiological features
found with cerebellar PAs, which have characteristic-
ally well-circumscribed lesions demonstrating a mural
nodule with a unique or multiple macrocysts. The
solid portion obviously demonstrates homogeneous
contrast enhancement. Vermis PAs are inclined to
have less cystic components, with significant enhance-
ments such as imaging features found in medulloblas-
tomas and ependymomas (Fig. 1a–c). Our goal was to
evaluate the extent of resection under the aid of
fluorescein sodium in the three patients with vermis
PAs. Postoperative MRI was obtained within 72 h for
the assessment of residual tumor. Tumor gross total
resection (GTR) was defined as no residual enhanced
tumor on the postoperative Gd-enhanced T1-weighted
MRI (Fig. 1d–f ).
Surgical procedure
Fluorescein sodium (5 mg/kg) prior to general anesthesia
was administered into the central venous line. Craniot-
omy was performed conventionally. Following the ad-
ministration of fluorescein sodium, fluorescence could
be visualized by utilizing a yellow fluorescence micro-
scope system. The resection was executed approximately
1 h after administration of fluorescein sodium with the
aid of white light in conjunction with intraoperative
fluorescence guidance (Fig. 2). In the three cases, tumors
were removed piece by piece based on fluorescein iden-
tification. Resection was continued until no highly visible
fluorescent tissue remained (Fig. 3).
Results
High fluorescent staining of the lesion was documented,
which markedly enhanced tumor visibility. We decided
to remove all fluorescent tissue as tumor cells could not
be excluded during frozen section. Pale fluorescence or
absence of fluorescence staining of the tumor had not
been observed in our cases. Fluorescein staining pro-
vided intraoperative identification of residual tumor tis-
sue, which is confirmed by the data presented here. The
case presentation was chosen to display the impression
of fluorescence: the views under the white light (Fig 2a,
c) do not explicitly show a lesion, but the views under
the yellow filter (Fig. 2b, d) depict the fluorescent signal
that clearly demarcates the targeted area. No patients
showed significant residual tumor tissue upon postoper-
ative MRI examination. We did not observe any adverse
Fig. 1 Preoperative axial (a), sagittal (b), and coronal (c) MRI illustrating a large mass with an enhancing solid mass and associated cyst in the
fourth ventricle. Postoperative MRI (d–f) revealing complete removal of the tumor
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or allergic reactions or disorders related to the adminis-
tration of fluorescein sodium.
Discussion
PAs, which are tending to arise in the cerebellum, are a
distinct histologic and biologic subset of gliomas [1].
When diagnoses are made, most of the patients have clin-
ical signs of cerebellar dysfunction, such as appendicular
dysmetria, truncal steadiness, decreased vision, extraocu-
lar movement abnormalities, dysmetria, and gait unsteadi-
ness [2]. These tumors easily give rise to hydrocephalus,
followed by increased intracranial pressure. It is well
known that the prognosis of PA is evidently associated
with radical resection. The prognosis of partially extir-
pated PA is not satisfactory despite subsequent treatment
consisting of radiotherapy and chemotherapy [3]. In order
to increase the resection rate of giant vermis PAs, we used
yellow fluorescein techniques during surgery.
The surgical management of PAs has long been a sub-
ject of affirmation. Patients with PAs have the best over-
all survival if the tumor is completely resected [4].
Complete removal is associated with a 10-year survival
rate of 100% and a low recurrence rate, whereas almost
half of the patients with partially removed PAs will have
recurrence [5]. Malignant transformation after partial re-
section due to residual tumor tissue has been constantly
mentioned in the published literatures due to residual
tumor tissue [6, 7]. An accurate diagnosis may not be
granted if the partial removal does not include the ma-
lignant portion of the tumor [8]. Thus, radical resection
to forestall recurrence is essential [9, 10].
Intraoperative use of fluorescein sodium can help to
enhance the fidelity of tumor tissue, and enable
complete resection of vermis PAs. With the develop-
ment of novel surgical tools, the surgical resection rate
has increasingly risen [11, 12]. Methods to differentiate
tumors from normal brain tissue are still being sought.
Substances such as fluorescein can be employed for in-
traoperative visualization of tumor tissue [13]. Fluores-
cein can permeate damaged areas of the blood-brain
barrier, which are representative of tumor tissue, and re-
sult in effective and easier resection. This minimizes
normal tissue manipulation and facilitates microsurgical
dissection of the lesion from the surrounding paren-
chyma. Due to their normal structures, it is important to
identify the margin between normal tissue and tumor.
Fluorescein sodium can aid in differentiation so that
permanent deficit due to surgical manipulation can be
avoided.
PAs are generally well-circumscribed tumors that have
a low growth rate. On imaging, they often present as a
small solid nodule accompanied by a big cyst [14]. The
borders of vermis PAs with less cystic elements in our
series of patients were not clear under microscopy. Some
studies reported that fluorescein sodium reduced surgi-
cal difficulty and increased resection rate compared to
studies where it was not used. Fluorescence-guided
surgery is an easy procedure and does not require add-
itional time and instrumentation. Utilizing a microsurgi-
cal mirror, identification of residual fluorescent tissue
within the resection cavity facilitates complete resection
and can be verified on postoperative MRI. In the current
study, the data suggests that the use of FL was safer and
increased resection of vermis PAs compared to simple
standard microsurgery.
The mean duration of surgery for the fluorescein
group was shorter than that of the standard microsur-
gery group. Complete resection of contrast-enhanced
tumor tissue has been repeatedly indicated to be crucial
Fig. 2 Microsurgical photograph of the vermis under white light (a,
c) and the yellow 560 filter (b, d) from intermediate stages of tumor
resection. Residual tumor tissue (arrow) was identified under the
yellow 560 filter compared with white light (b, d)
Fig. 3 Intraoperative microsurgical photograph displaying total
resection of the tumor and the exit of the midbrain aqueduct
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for lowering recurrence rate, PFS, and the length and
quality of survival [15]. Despite the limited number of
patients in our data, this study illustrated that fluores-
cein facilitated complete removal of vermis PAs. Here,
we rate a rate of 100% for positive fluorescein staining
under the yellow 560 nm filter. Absence or insufficient
tumor fluorescence staining during resection was not
observed in our three patients.
Fluorescein has been increasingly reported to obvi-
ously improve the efficacy of fluorescence-guided resec-
tion of malignant gliomas [16–18]. Fluorescein gathers
in a disrupted blood-brain barrier area as a result of
pathologically increased vascular permeability [19, 20].
We injected a low dose of fluorescein sodium (5 mg/kg)
and used the dedicated surgical microscope with a yel-
low 560 nm filter. It was relatively easy to visualize the
discretely fluorescein-stained tumor tissue. The visible
fluorescence effect accurately confirmed the tumor loca-
tions through pathology and resulted in decreased surgi-
cal damage to brain tissue surrounding the tumor.
Bright fluorescence signaling was observed in all pa-
tients, which aided in the identification of a suspicious
lesion. Accordingly, the application of fluorescein so-
dium for contrast-enhancing vermis PAs could confirm
the surgical margins and allow for safe and thorough
resection. To the best of our knowledge, our group has
provided the first data on the efficacy of fluorescein
sodium for the resection of vermis PAs. None of the
patients reported any systemic or local side-effects. Any
adverse effects or anaphylactic disorders were not
observed.
The content of this study surpassed that of a simple
feasibility study for the vermis PAs. We are well aware
of the limitations of our study; namely, this study is
retrospective and has no qualitative statement regarding
fluorescent staining in the vermis PAs.
Conclusions
Our clinical data illustrates the safety and utility of fluor-
escein sodium in the identification and resection of ver-
mis PAs. The application of fluorescein sodium was a
well-tolerated procedure that allowed for a greater ex-
tension of resection and a significantly reduced perman-
ent deficit rate owing to the identification of crucial
structures. A long-term follow up with a larger number
of patients is necessary to establish the significance of
fluorescein sodium-guided surgery for patients with ver-
mis PAs.
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